Mn Services Vermogensbeheer B.V. Trims Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Mn Services Vermogensbeheer B.V. decreased its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 105,704 shares of the medical instruments supplier's stock after selling 8,100 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Becton, Dickinson and Company were worth $24,213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Bank of Jackson Hole Trust bought a new stake in Becton, Dickinson and Company in the fourth quarter worth $25,000. REAP Financial Group LLC increased its holdings in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares during the period. Sierra Ocean LLC purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. Picton Mahoney Asset Management increased its position in Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after buying an additional 54 shares in the last quarter. Finally, Nexus Investment Management ULC purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth $34,000. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares in the company, valued at $964,107.36. The trade was a 8.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Shan sold 1,166 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president now owns 4,575 shares in the company, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Down 1.2%

Becton, Dickinson and Company stock traded down $2.09 during midday trading on Tuesday, reaching $170.01. 3,781,553 shares of the stock traded hands, compared to its average volume of 1,987,243. The firm has a market cap of $48.73 billion, a PE ratio of 12.21, a price-to-earnings-growth ratio of 1.30 and a beta of 0.25. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The company has a 50-day simple moving average of $182.46 and a two-hundred day simple moving average of $212.60. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the firm posted $3.17 earnings per share. The business's revenue for the quarter was up 4.5% compared to the same quarter last year. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.45%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's payout ratio is presently 79.39%.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wells Fargo & Company downgraded Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. Morgan Stanley reduced their price objective on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their price target for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Finally, Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.